BioAlliance Pharma to present at the French-Norwegian Interdisciplinary Symposium on Nano and Micro Frontiers in Biology and Medicine
(Nanowerk News) BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced that it will present its nanoparticle technology and the latter's advantages in therapeutic applications at the French-Norwegian Interdisciplinary Symposium on Nano and Micro Frontiers in Biology and Medicine, to take place in Bergen, Norway, from August 31 to September 2, 2009.
Medical applications of nano- and microtechnology are undergoing unprecedented growth worldwide, with the first drugs based on these platforms now reaching the market. By positioning itself within this sector, BioAlliance Pharma is forging a reputation as a pioneer in France and the rest of Europe. The company's proprietary nanoparticle technologies enable it to offer innovative therapeutics solutions for parenteral or oral administration in oncology, infectious diseases and supportive care.
During this interdisciplinary symposium, BioAlliance Pharma will present its latest advances in the field of chemotherapy - notably its slow-release nanoparticle system for orally administered irinotecan and the "Transdrug" parenteral system. The symposium also constitutes an opportunity for the company to develop its network of experts with particular R&D expertise in these new modes of drug delivery.
About the French-Norwegian Interdisciplinary Symposium on Nano and Micro Frontiers in Biology and Medicine
The "French-Norwegian Interdisciplinary Symposium on Nano and Micro Frontiers in Biology and Medicine" is being organized with the support of the French Embassy in Oslo and the Franco-Norwegian Foundation for Research, Innovation and Industrial Development (FFN-FFS).
About BioAlliance Pharma
As a preferred partner for hospital-based specialists, BioAlliance Pharma (Paris:BIO) is a company which develops and markets innovative products in France, especially in the fields of opportunistic infections and chemotherapy complications. In areas where medical needs are insufficiently met, our targeted approaches help overcome drug resistance and improve patient health & quality of life. BioAlliance Pharma’s ambition is to become a leading player in these fields by coupling innovation to patient needs.
Printer-friendly
E-mail this article
Daily News Email Digest
News Feeds
Join us on Facebook
Follow us on Twitter
